Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Hepatocellular Carcinoma
Pharma
Junshi, Coherus move Loqtorzi closer to another approval
Junshi revealed that a phase 3 trial of Loqtorzi plus Avastin prolonged the survival of first-line patients with hepatocellular carcinoma.
Kevin Dunleavy
Jun 12, 2024 11:45am
AZ's Imfinzi proves its worth in another liver cancer population
Nov 9, 2023 11:00am
FDA accepts AZ's application for tremelimumab in liver cancer
Apr 25, 2022 9:29am
Lilly scores targeted liver cancer win for Cyramza
May 13, 2019 12:02pm
BMS, leading I-O in liver cancer, nabs Opdivo 'priority' tag
May 25, 2017 9:42am
